ScreenerHero

LGVN Longeveron Inc.

NAS · US · Healthcare · Biotechnology · longeveron.com
2.440USD+3.83%Mkt Cap: 7.78M $P/E: —

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogenei…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap7.78M USD
Enterprise Value-2.00M USD
Revenue (TTM)1.19M USD
Gross Profit803.00K USD
Net Income (TTM)-22.70M USD
Revenue/Share0.49 USD
Last Price2.440 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees38
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.54
PEG—
EV/EBITDA0.09
EV/Revenue-1.69
P/S6.31
P/B0.72
EPS (TTM)-9.23
EPS (Forward)-1.53
52W Range
2.3001% of range12.30
52W High12.30 USD
52W Low2.300 USD
Profitability
Gross Margin66.97%
Oper. Margin-2150.17%
EBITDA Margin0.00%
Profit Margin-1893.58%
ROE-400.07%
ROA-221.26%
Growth
Revenue Growth-9.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.64M USD
CapEx (TTM)595.00K USD
FCF Margin-977.54%
FCF Yield-149.16%
Net Debt-9.50M USD
Net Debt/EBITDA0.42
Balance Sheet
Debt/Equity0.15
Current Ratio2.63
Quick Ratio2.35
Book Value/Sh3.28 USD
Cash/Share3.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateAug 27, 2026
Analyst Consensus
Rating—
Target (Mean)61.25 USD
Upside (mean)+2410.2%
Target Range42.50 USD – 80.00 USD
42.50+2410.2% to mean80.00
# Analysts2
Ownership
Shares Out.3.04M
Float2.38M
Insiders15.14%
Institutions22.64%
Short Interest
Short Ratio2.9d
Short % Float7.27%
Short % Out.6.71%
Shares Short213.78K
Short (prev mo.)169.99K
Technical
SMA 505.960 (-59.1%)
SMA 2006.995 (-65.1%)
Beta-0.20
S&P 52W Chg16.45%
Avg Vol (30d)95.74K
Avg Vol (10d)86.30K
Technical Indicators
RSI (14)27.0
MACD-1.1174
MACD Signal-1.0933
MACD Hist.-0.0240
BB Upper7.864 USD
BB Middle3.873 USD
BB Lower-0.1165 USD
BB Width206.02%
ATR (14)0.4603 USD
Vol Ratio (20d)0.53x